Continued work looking at cell type-specific activation of mTOR complexes and introduction of mTORC2 or dual mTORC1/mTORC2 complex inhibitors is likely to yield more therapeutic options for SLE patients. This evidence concerns the gene MTOR and systemic lupus erythematosus.